Page 36 - Read Online

Page 16 of 18 Llamoza-Torres et al. Metab Target Organ Damage 2024;4:40 https://dx.doi.org/10.20517/mtod.2024.64

systematic review. Clin Gastroenterol Hepatol 2012;10:1342-59.e2. DOI PubMed PMC
78. Pennisi G, Enea M, Romero-Gomez M, et al. Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a
retrospective competing risks analysis. Aliment Pharmacol Ther 2022;55:604-15. DOI PubMed
79. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of
patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389-97.e10. DOI PubMed PMC
80. Sanyal AJ, Harrison SA, Ratziu V, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the
simtuzumab trials. Hepatology 2019;70:1913-27. DOI PubMed
81. Vitellius C, Desjonqueres E, Lequoy M, et al. MASLD-related HCC: multicenter study comparing patients with and without
cirrhosis. JHEP Rep 2024;6:101160. DOI PubMed PMC
82. Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated
with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2016;14:124-31.e1. DOI PubMed PMC
83. Wong CR, Njei B, Nguyen MH, Nguyen A, Lim JK. Survival after treatment with curative intent for hepatocellular carcinoma among
patients with vs without non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017;46:1061-9. DOI PubMed
84. Stine JG, Wentworth BJ, Zimmet A, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic
steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 2018;48:696-703. DOI PubMed PMC
85. Tan DJH, Ng CH, Lin SY, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver
disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol 2022;23:521-30. DOI PubMed PMC
86. Kodama T, Takehara T. Molecular genealogy of metabolic-associated hepatocellular carcinoma. Semin Liver Dis 2024;44:147-58.
DOI PubMed PMC
87. Oh S, Baek YH, Jung S, et al. Identification of signature gene set as highly accurate determination of metabolic dysfunction-
associated steatotic liver disease progression. Clin Mol Hepatol 2024;30:247-62. DOI PubMed PMC
88. Huang G, Wallace DF, Powell EE, Rahman T, Clark PJ, Subramaniam VN. Gene variants implicated in steatotic liver disease:
opportunities for diagnostics and therapeutics. Biomedicines 2023;11:2809. DOI PubMed PMC
89. Stender S, Loomba R. PNPLA3 genotype and risk of liver and all-cause mortality. Hepatology 2020;71:777-9. DOI PubMed PMC
90. Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome Med 2020;12:44. DOI PubMed
PMC
91. Yang J, Trépo E, Nahon P, et al. PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies
and severity of underlying liver diseases. Int J Cancer 2019;144:533-44. DOI PubMed
92. Bianco C, Jamialahmadi O, Pelusi S, et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using
polygenic risk scores. J Hepatol 2021;74:775-82. DOI PubMed
93. Thomas CE, Diergaarde B, Kuipers AL, et al. NAFLD polygenic risk score and risk of hepatocellular carcinoma in an East Asian
population. Hepatol Commun 2022;6:2310-21. DOI PubMed PMC
94. Chalasani N, Vilar-Gomez E, Loomba R, et al. PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the
risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease. Hepatology 2024;80:1212-26. DOI
PubMed
95. Muthiah MD, Sanyal AJ. Burden of disease due to nonalcoholic fatty liver disease. Gastroenterol Clin North Am 2020;49:1-23. DOI
PubMed
96. Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic
review and meta-analysis. Lancet Gastroenterol Hepatol 2019;4:389-98. DOI PubMed
97. Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a
systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:739-52. DOI PubMed
98. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat
Rev Gastroenterol Hepatol 2018;15:11-20. DOI PubMed
99. Unalp-Arida A, Ruhl CE. Patatin-like phospholipase domain-containing protein 3 I148M and liver fat and fibrosis scores predict liver
disease mortality in the U.S. population. Hepatology 2020;71:820-34. DOI PubMed
100. Petta S, Armandi A, Bugianesi E. Impact of PNPLA3 I148M on clinical outcomes in patients with MASLD. Liver Int 2024;Online
ahead of print. DOI PubMed
101. Lavrado NC, Salles GF, Cardoso CRL, et al. Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with
MASLD and type 2 diabetes mellitus. Liver Int 2024;44:1042-50. DOI PubMed
102. Seko Y, Yamaguchi K, Shima T, et al. Differential effects of genetic polymorphism on comorbid disease in metabolic dysfunction-
associated steatotic liver disease. Clin Gastroenterol Hepatol 2024;22:1436-43.e4. DOI PubMed
103. Seko Y, Yamaguchi K, Shima T, et al. Clinical utility of genetic variants in PNPLA3 and TM6SF2 to predict liver-related events in
metabolic dysfunction-associated steatotic liver disease. Liver Int 2024;Online ahead of print. DOI PubMed
104. Sripongpun P, Kim WR, Mannalithara A, et al. The steatosis-associated fibrosis estimator (SAFE) score: a tool to detect low-risk
NAFLD in primary care. Hepatology 2023;77:256-67. DOI PubMed PMC
105. Sripongpun P, Kaewdech A, Udompap P, Kim WR. Characteristics and long-term mortality of individuals with MASLD, MetALD,
and ALD, and the utility of SAFE score. JHEP Rep 2024;6:101127. DOI PubMed PMC
106. Kaplan DE, Teerlink CC, Schwantes-An TH, et al. Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction-
associated steatotic liver disease. Hepatol Commun 2024;8:e0487. DOI PubMed PMC
107. Hsu CK, Kuo CC, Lai CC. Refining metabolic syndrome trait definitions in MASLD: a call for greater precision in cardiovascular